Clin Osteol 2022; 27(1): 13-16 | DOI: 10.36290/clo.2022.002

A need for predictive and personalized approach in osteoporosis treatment: individual treatment planReview articles

Pikner Richard1,2,3, ©vagr Martin4, Novák Vladimír1, Vachek Jan5
1 Department of Clinical Biochemistry and Bone Metabolism, Klatovska Hospital, Klatovy, Czech Republic
2 Department of Clinical Biochemistry and Haematology, Faculty of Medicine Pilsen, Charles University Prague, Pilsen, Czech Republic
3 Faculty of Health Care Studies, University of West Bohemia, Pilsen, Czech Republic
4 Department of Orthopaedics, Klatovska Hospital, Klatovy, Czech Republic
5 Department of Internal Medicine, Klatovska Hospital, Klatovy, Czech Republic

Osteoporosis is a frequent, multifactorial disease and represents a significant and increasing healthcare burden in Europe. For osteoporosis treatment several drugs groups (SERM: bisphosphonates, denosumab, teriparatide) have been approved with different biological effects and further are expected. The question if every medication is suitable for all patients, is opened. We may stratify patients by individual fracture risk assessment but often there many others individual factors affecting medication choice. Age, life expectancy, falls, kidney function are very important. Preparing individual treatment plans for each patient is the way how to handle with it. In younger osteoporotic women we have to expect 20-25 years of care and sequential therapy, long term therapy with "drug holiday" is to be considered. This new strategy should be accompanied by more flexible reimbursement rules.

Published: June 11, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pikner R, ©vagr M, Novák V, Vachek J. A need for predictive and personalized approach in osteoporosis treatment: individual treatment plan. Clinical Osteology. 2022;27(1):13-16. doi: 10.36290/clo.2022.002.
Download citation

References

  1. Hernlund E, Svedbom A, Ivergård M J et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8(1): 136. Dostupné z DOI: <http://doi: 10.1007/s11657-013-0136-1>. Go to original source... Go to PubMed...
  2. Svedbom A, Hernlund E, Ivergård M et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8(1): 137. Available from DOI: <http://doi:10.1007/s11657-013-0137-0>. Go to original source... Go to PubMed...
  3. Åkesson K, Marsh D, Mitchell PJ et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 2013; 24(8): 2135-5212. Available from DOI: <http://doi10.1007/s00198-013-2348-z>. Go to original source... Go to PubMed...
  4. Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, Preventive and Personalised Medicine as the hardcore of 'Horizon 2020': EPMA position paper. EPMA Journal 2014; 5(1): 6. Available from DOI: <http://doi10.1186/1878-5085-5-6>. Go to original source... Go to PubMed...
  5. FRAX [Internet]. Available from WWW: <https://www.sheffield.ac.uk/FRAX>.
  6. Garvan Fracture Risk Calculator. [Internet]. Available from WWW: <https://www.garvan.org.au/promotions/bone-fracturerisk/calculator/
  7. QFracture-2016 [Internet]. Available from WWW: https://www.qfracture.org>.
  8. Nguyen TV. Individualized fracture risk assessment: Stateof-the-art and room for improvement. Osteoporos Sarcopenia 2018; 4(1): 2-10. Available from DOI: <http://doi 10.1016/j.afos.2018.03.001>. Go to original source... Go to PubMed...
  9. Harvey NC, Odén A, Orwoll E et al. Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res 2018; 33(3): 510-516. Available from DOI: <http://doi10.1002/jbmr.3331>. Go to original source... Go to PubMed...
  10. Hollis BW, Wagner CL. The Role of the Parent Compound Vitamin D with Respect to Metabolism and Function: Why Clinical Dose Intervals Can Affect Clinical Outcomes. J Clin Endocrinol Metab 2013; 98(12): 4619-4628. Available from DOI: <http://doi:10.1210/jc.2013-2653>. Go to original source... Go to PubMed...
  11. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metabol 2011; 96(7): 1911-1930. Available from DOI: <http://doi 10.1210/jc.2011-0385>. Go to original source... Go to PubMed...
  12. Koduah P, Paul F, Dörr JM. Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA J 2017; 8(4): 313-325. Available from DOI: <http://doi10.1007/s13167-017-0120-8>. Go to original source... Go to PubMed...
  13. Grey A, Bolland MJ, Horne A et al. Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. J Bone Miner Res 2022; 37(1): 3-11. Available from DOI: <http://doi10.1002/jbmr.4453>. Go to original source... Go to PubMed...
  14. Kim TY, Bauer DC, McNabb BL et al. Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. J Bone Miner Res 2019; 34(5): 810-816. Available from DOI: <http://doi10.1002/jbmr.3654>. Go to original source... Go to PubMed...
  15. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diab Endocrinol 2017; 5(11): 898-907. Available from DOI: <http://doi10.1016/S2213-8587(17)30188-2>. Go to original source... Go to PubMed...
  16. Tsourdi E, Langdahl B, Cohen-Solal M et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone 2017; 105: 11-17. Available from DOI: <http://doi10.1016/j.bone.2017.08.003>. Go to original source... Go to PubMed...
  17. Cummings SR, Ferrari S, Eastell R et al. Vertebral Fractures after Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension: VERTEBRAL FRACTURES AFTER DENOSUMAB DISCONTIN- UATION. J Bone Miner Res 2018; 33(2): 190-198. Available from DOI: <http://doi10.1002/jbmr.3337>. Go to original source... Go to PubMed...
  18. Eastell R, Walsh JS. Anabolic treatment for osteoporosis: teriparatide. Clin Cases Miner Bone Metab 2017; 14(2):173-178. Available from DOI: <http://doi10.11138/ccmbm/2017.14.1.173>. Go to original source... Go to PubMed...
  19. Haas AV, LeBoff MS. Osteoanabolic Agents for Osteoporosis. J Endocr Soc 2018; 2(8): 922-932. Available from DOI: <http://doi10.1210/js.2018-00118>. Go to original source... Go to PubMed...
  20. Evenity (romosozumab). Souhrn charakteristických vlastností léku. EMA (SUKL). Available from WWW: <http://www.ema.europa.eu/en/documents/product-information/evenity-epar-product-information_cs.pdf>.
  21. Golubnitschaja O, Baban B, Boniolo G et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J 2016; 7(1): 23. Available from DOI: <http://doi10.1186/s13167-016-0072-4>. Go to original source... Go to PubMed...
  22. Golubnitschaja O, Watson ID, Topic E et al. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J 2013; 4(1): 12. Available from DOI: <http://doi10.1186/1878-5085-4-12>. Go to original source... Go to PubMed...
  23. Grech G, Zhan X, Yoo BC et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J 2015; 6(1): 9. Available from DOI: <http://doi10.1186/s13167-015-0030-6>. Go to original source... Go to PubMed...




Clinical Osteology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.